H.C. Wainwright initiated coverage of 60 Degrees Pharmaceuticals with a Neutral rating and no price target. 60 Degrees is a pharmaceutical company focused on the development and commercialization of new small molecule therapeutics for the treatment and prevention of infectious diseases, the analyst tells investors in a research note. The firm awaits further development of Arakoda into other indications before recommending the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SXTP:
- 60 Degrees Pharmaceuticals to present data on tafenoquine antimalarial regimen
- 60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston
- 60 Degrees Pharmaceuticals Inc trading resumes
- 60 Degrees Pharmaceuticals suspends tafenoquine trial for COVID-19
- 60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases
